A novel SEZ6-targeting ADC carrying a topoisomerase I inhibitor is being developed for neuroendocrine and neuronal solid tumors (e.g., SCLC, glioblastoma, NECs). SEZ6’s selective, consistent expression and efficient internalization may improve efficacy and safety over prior ADCs.
[Credit: AbbVie]
[Credit: AbbVie]
November 11, 2025 at 12:11 PM
A novel SEZ6-targeting ADC carrying a topoisomerase I inhibitor is being developed for neuroendocrine and neuronal solid tumors (e.g., SCLC, glioblastoma, NECs). SEZ6’s selective, consistent expression and efficient internalization may improve efficacy and safety over prior ADCs.
[Credit: AbbVie]
[Credit: AbbVie]
In observance of Veterans Day, the Sacramento Cultural and Linguistics Center will be closed tomorrow.
We take this day to honor and thank all who have served our country with courage and dedication. 💙❤️
Regular operations will resume the following day.
#VeteransDay #SCLC #ThankYouVeterans
We take this day to honor and thank all who have served our country with courage and dedication. 💙❤️
Regular operations will resume the following day.
#VeteransDay #SCLC #ThankYouVeterans
November 10, 2025 at 9:55 PM
In observance of Veterans Day, the Sacramento Cultural and Linguistics Center will be closed tomorrow.
We take this day to honor and thank all who have served our country with courage and dedication. 💙❤️
Regular operations will resume the following day.
#VeteransDay #SCLC #ThankYouVeterans
We take this day to honor and thank all who have served our country with courage and dedication. 💙❤️
Regular operations will resume the following day.
#VeteransDay #SCLC #ThankYouVeterans
Excited to share our new review on our current understanding of small cell lung cancer (SCLC) heterogeneity and plasticity, led by Gina Duronio in the lab: www.tandfonline.com/doi/full/10....
November 10, 2025 at 6:29 PM
Excited to share our new review on our current understanding of small cell lung cancer (SCLC) heterogeneity and plasticity, led by Gina Duronio in the lab: www.tandfonline.com/doi/full/10....
Mlot-Mroz even had a "Katie Daviscourt" moment when he attended a Poor Peoples' march and was reportedly attacked by civil rights protesters. This "vicious attack by the radical left" made national news...the only problem was, it was all a lie intended to discredit the civil rights movement.
November 8, 2025 at 9:18 PM
Mlot-Mroz even had a "Katie Daviscourt" moment when he attended a Poor Peoples' march and was reportedly attacked by civil rights protesters. This "vicious attack by the radical left" made national news...the only problem was, it was all a lie intended to discredit the civil rights movement.
Yes, institution building is hard. Got to be enough ADL and SCLC alumn with knowledge and people who see the value.
November 7, 2025 at 6:56 PM
Yes, institution building is hard. Got to be enough ADL and SCLC alumn with knowledge and people who see the value.
This paper is very interesting for nsclc. In Brasil, durvalumab, anti PDL1, was only approved this year for nsclc, previously just for sclc. Im not sure if there are studies on its specific interaction whit the covid19 mRNA vaccine but it looks very promising. Pfizer cloud support research like this
November 7, 2025 at 3:36 PM
This paper is very interesting for nsclc. In Brasil, durvalumab, anti PDL1, was only approved this year for nsclc, previously just for sclc. Im not sure if there are studies on its specific interaction whit the covid19 mRNA vaccine but it looks very promising. Pfizer cloud support research like this
Our news of the week: Poster presented at the first annual @sosclc-aecc.bsky.social Symposium, showcasing the work of Ana Lopez Garza and Hugo Thabussot on #SCLC research, conducted as part of the #AECC 70% Survivorship Challenge. @vhio.bsky.social #peptomyc
November 7, 2025 at 12:03 PM
Our news of the week: Poster presented at the first annual @sosclc-aecc.bsky.social Symposium, showcasing the work of Ana Lopez Garza and Hugo Thabussot on #SCLC research, conducted as part of the #AECC 70% Survivorship Challenge. @vhio.bsky.social #peptomyc
Yesterday, Team Caity stopped by the SCLC's Union Job Fair! Along with all the other amazing work the SCLC does, it's great to see them work with local organizations and the city to connect people with more opportunities.
November 7, 2025 at 1:07 AM
Yesterday, Team Caity stopped by the SCLC's Union Job Fair! Along with all the other amazing work the SCLC does, it's great to see them work with local organizations and the city to connect people with more opportunities.
Historical example, when the SCLC was in Cicero, Illinois organizing and mobilizing around ending segregation in the neighborhoods and businesses.
A lot of folk not just this random man took issue. People keep creating a monolithic egalitarian, radical, internationalist negro… THAT WAS NEVER TRUE🤣
A lot of folk not just this random man took issue. People keep creating a monolithic egalitarian, radical, internationalist negro… THAT WAS NEVER TRUE🤣
November 6, 2025 at 7:56 PM
Historical example, when the SCLC was in Cicero, Illinois organizing and mobilizing around ending segregation in the neighborhoods and businesses.
A lot of folk not just this random man took issue. People keep creating a monolithic egalitarian, radical, internationalist negro… THAT WAS NEVER TRUE🤣
A lot of folk not just this random man took issue. People keep creating a monolithic egalitarian, radical, internationalist negro… THAT WAS NEVER TRUE🤣
November is Lung Cancer Awareness Month—a time to raise awareness and advance care through education.
Join PeerView’s Innovation Takes the Lead in SCLC live at #NACLC25 or online Dec 6, 11:30 AM CST with Drs. Stephen V. Liu, Jennifer W. Carlisle, and Anne Chiang.
🔗 https://bit.ly/SCLC25-T
Join PeerView’s Innovation Takes the Lead in SCLC live at #NACLC25 or online Dec 6, 11:30 AM CST with Drs. Stephen V. Liu, Jennifer W. Carlisle, and Anne Chiang.
🔗 https://bit.ly/SCLC25-T
November 5, 2025 at 12:40 PM
November is Lung Cancer Awareness Month—a time to raise awareness and advance care through education.
Join PeerView’s Innovation Takes the Lead in SCLC live at #NACLC25 or online Dec 6, 11:30 AM CST with Drs. Stephen V. Liu, Jennifer W. Carlisle, and Anne Chiang.
🔗 https://bit.ly/SCLC25-T
Join PeerView’s Innovation Takes the Lead in SCLC live at #NACLC25 or online Dec 6, 11:30 AM CST with Drs. Stephen V. Liu, Jennifer W. Carlisle, and Anne Chiang.
🔗 https://bit.ly/SCLC25-T
📢 Happening Today!
Join us 17:00 CET for the webinar: “Management of SCLC in the Immunotherapy Era”
💡 Hear from global experts on RT, systemic therapies & more!
👉 Register free: bit.ly/3IWaD6z
#RadiationOncology #SCLC #Immunotherapy #MedicalEducation
Join us 17:00 CET for the webinar: “Management of SCLC in the Immunotherapy Era”
💡 Hear from global experts on RT, systemic therapies & more!
👉 Register free: bit.ly/3IWaD6z
#RadiationOncology #SCLC #Immunotherapy #MedicalEducation
November 5, 2025 at 12:27 PM
📢 Happening Today!
Join us 17:00 CET for the webinar: “Management of SCLC in the Immunotherapy Era”
💡 Hear from global experts on RT, systemic therapies & more!
👉 Register free: bit.ly/3IWaD6z
#RadiationOncology #SCLC #Immunotherapy #MedicalEducation
Join us 17:00 CET for the webinar: “Management of SCLC in the Immunotherapy Era”
💡 Hear from global experts on RT, systemic therapies & more!
👉 Register free: bit.ly/3IWaD6z
#RadiationOncology #SCLC #Immunotherapy #MedicalEducation
🧠 SCLC remains one of the most aggressive cancers.
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
November 5, 2025 at 8:15 AM
🧠 SCLC remains one of the most aggressive cancers.
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
That is truly a great idea. The ACLU, SCLC, Urban League, & other legacy Civil Rights Orgs have been trying that within their budget means. The idea is to create MORE battle fronts than the Trump Crime Syndicate can "intelligently" fight! MAGA has more money but- more of Trump's stupid too! 💪✊🗽
November 4, 2025 at 10:44 PM
That is truly a great idea. The ACLU, SCLC, Urban League, & other legacy Civil Rights Orgs have been trying that within their budget means. The idea is to create MORE battle fronts than the Trump Crime Syndicate can "intelligently" fight! MAGA has more money but- more of Trump's stupid too! 💪✊🗽
@lisagetspolitik again, please go read the book This Non-Violent Stuff'll Get You Killed. I'll happily send you a copy.
Because you are completely misrepresenting not only King but the SCLC as a whole here.
Because you are completely misrepresenting not only King but the SCLC as a whole here.
November 3, 2025 at 11:33 PM
@lisagetspolitik again, please go read the book This Non-Violent Stuff'll Get You Killed. I'll happily send you a copy.
Because you are completely misrepresenting not only King but the SCLC as a whole here.
Because you are completely misrepresenting not only King but the SCLC as a whole here.
On this #LungCancerAwarenessMonth, we highlight exciting findings from Vignesh Sakthivelu and colleagues showing that SCLC cells can form functional synapses with neurons — allowing cancer cells to use neural signals to drive their growth and revealing a new layer of tumor–neuron communication.
Finally out at @nature.com! Co-led with @motorilab.bsky.social, Max Anstötz, Silvio Rizzoli, Christian Rheinardt and Filippo Beleggia, we show that SCLC hijack glutamatergic synapses for proliferation advantage. Congrats to all involved! @cecad.bsky.social www.nature.com/articles/s41...
Functional synapses between neurons and small cell lung cancer - Nature
Small cell lung cancer cells form functional synapses with glutamatergic neurons, receiving synaptic transmissions and deriving a proliferative advantage from these interactions.
www.nature.com
November 3, 2025 at 7:10 PM
On this #LungCancerAwarenessMonth, we highlight exciting findings from Vignesh Sakthivelu and colleagues showing that SCLC cells can form functional synapses with neurons — allowing cancer cells to use neural signals to drive their growth and revealing a new layer of tumor–neuron communication.
Book 66: Bearing the Cross: Martin Luther King Jr. and the Southern Christian Leadership Conference by David J. Garrow (1987 Pulitzer for Biography) Recommended. A detailed blow-by-blow account of the history of MLK Jr and SCLC from the Birmingham bus boycott to MLK Jr’s assassination.
November 1, 2025 at 12:56 PM
Book 66: Bearing the Cross: Martin Luther King Jr. and the Southern Christian Leadership Conference by David J. Garrow (1987 Pulitzer for Biography) Recommended. A detailed blow-by-blow account of the history of MLK Jr and SCLC from the Birmingham bus boycott to MLK Jr’s assassination.
New NEJM study: Tarlatamab, a bispecific T-cell engager, vs. chemotherapy in phase 3 for post-platinum SCLC. Accelerated approval shines light on hope! 🌟 PMID:40454646, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2502099 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2502099
No description available
doi.org
November 1, 2025 at 2:10 AM
Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis - Linjing Zhou, Yuwei Li, Le Wang, Kaiyan Chen, Shichao Zhou, Yunfei Chen, Jing Sun, Yunfeng Tong, Yun Fan, 2025
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy, with or without angiogenesis inhibitors, have been investigated as the first-line tr...
doi.org
October 31, 2025 at 7:15 AM
Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
The @fda.gov has approved Zepzelca® in combo with Tecentriq® or Tecentriq Hybreza® for the maintenance treatment of adult patients with ES-#SCLC. From @medicalprofref.bsky.social.
https://bit.ly/4hyXqxt
#lcsm #lungcancer
https://bit.ly/4hyXqxt
#lcsm #lungcancer
Zepzelca Plus Atezolizumab Approved for First-Line ES-SCLC Maintenance Therapy - Oncology Nurse Advisor
The approval was based on data from the phase 3 IMforte trial, which evaluated lurbinectedin plus atezolizumab in patients with first-line ES-SCLC.
bit.ly
October 30, 2025 at 4:10 PM
The @fda.gov has approved Zepzelca® in combo with Tecentriq® or Tecentriq Hybreza® for the maintenance treatment of adult patients with ES-#SCLC. From @medicalprofref.bsky.social.
https://bit.ly/4hyXqxt
#lcsm #lungcancer
https://bit.ly/4hyXqxt
#lcsm #lungcancer
PUSH would become the group that pushed Jackson into the national spotlight and his two presidential runs, while still working on economic justice issues. Operation Breadbasket died in 1972 after SCLC couldn’t keep it going without him.
October 29, 2025 at 2:59 PM
PUSH would become the group that pushed Jackson into the national spotlight and his two presidential runs, while still working on economic justice issues. Operation Breadbasket died in 1972 after SCLC couldn’t keep it going without him.
Ralph Abernathy took over SCLC and while he was a good man, he didn’t have a lot of big vision and wanted to consolidate control, pretty ineffectively. In 1971, he demanded that Jackson move from Chicago to Atlanta so Operation Breadbasket could be run from SCLC officers.
October 29, 2025 at 2:59 PM
Ralph Abernathy took over SCLC and while he was a good man, he didn’t have a lot of big vision and wanted to consolidate control, pretty ineffectively. In 1971, he demanded that Jackson move from Chicago to Atlanta so Operation Breadbasket could be run from SCLC officers.
By 1967, Operation Breadbasket had built $22 million in income each year in the black community from the wages paid to black workers in previously all-white stores. The previous year, Martin Luther King and the SCLC decided to take the idea to Chicago as part of its broader campaign up there.
October 29, 2025 at 2:58 PM
By 1967, Operation Breadbasket had built $22 million in income each year in the black community from the wages paid to black workers in previously all-white stores. The previous year, Martin Luther King and the SCLC decided to take the idea to Chicago as part of its broader campaign up there.
This idea was not invented by Sullivan or the SCLC but it did spread through them through different communities. I’ve seen it in research I’ve been doing on civil rights in Seattle.
October 29, 2025 at 2:56 PM
This idea was not invented by Sullivan or the SCLC but it did spread through them through different communities. I’ve seen it in research I’ve been doing on civil rights in Seattle.
This worked very well in Philadelphia. In 1962, the SCLC brought Sullivan down to Atlanta to teach them everything he knew. That became Operation Breadbasket. It was pretty successful.
October 29, 2025 at 2:55 PM
This worked very well in Philadelphia. In 1962, the SCLC brought Sullivan down to Atlanta to teach them everything he knew. That became Operation Breadbasket. It was pretty successful.
Neoaduvant Immunochemotherapy May Improve Outcomes in LS-SCLC
https://www.europesays.com/ie/151547/
Neoadjuvant immunochemotherapy may offer superior outcomes compared to concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung…
https://www.europesays.com/ie/151547/
Neoadjuvant immunochemotherapy may offer superior outcomes compared to concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung…
Neoaduvant Immunochemotherapy May Improve Outcomes in LS-SCLC - Ireland
Neoadjuvant immunochemotherapy may offer superior outcomes compared to concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung
www.europesays.com
October 29, 2025 at 2:15 PM
Neoaduvant Immunochemotherapy May Improve Outcomes in LS-SCLC
https://www.europesays.com/ie/151547/
Neoadjuvant immunochemotherapy may offer superior outcomes compared to concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung…
https://www.europesays.com/ie/151547/
Neoadjuvant immunochemotherapy may offer superior outcomes compared to concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung…